Rapid Screening of Consumer Products by GCxGC-HRT and Machine Learning Assisted Data Processing.

This work demonstrates high-throughput screening of personal care products to provide an overview of potential exposure. Sixty-seven products from five categories (body/fragrance oil, cleaning product, hair care, hand/body wash, lotion, sunscreen) were rapidly extracted and then analyzed using suspect screening by two-dimensional gas chromatography (GCxGC) high-resolution mass spectrometry (GCxGC-HRT). Initial peak finding and integration were performed using commercial software, followed by batch processing using the machine learning program Highlight. Highlight automatically performs background subtraction, chromatographic alignment, signal quality review, multidilution aggregation, peak grouping, and iterative integration. This data set resulted in 2,195 compound groups and 43,713 individual detections. Compounds of concern (101) were downselected and classified as mild irritants (29%), environmental toxicants/severe irritants (51%) and endocrine disrupting chemicals/carcinogens (20%). High risk compounds such as phthalates, parabens, and avobenzone were detected in 46 out of the 67 products (69%), and only 5 out of the 67 products (7%) listed these compounds on their ingredient labels. The Highlight results for the compounds of concern were compared to commercial software results (ChromaTOF) and 5.3% of the individual detections were discerned only by Highlight, demonstrating the strength of the iterative algorithm to effectively discover low-level signatures. Highlight provides a significant labor advantage, requiring only 2.6% of the time estimated for a largely manual workflow using commercial software. In order to address significant time needed for postprocessing assignment of identification confidence, a new machine-learning-based algorithm was developed to assess the quality of assigned library matches, and a balanced accuracy of 79% was achieved.

Newborn Screening for Duchenne Muscular Dystrophy: First Year Results of a Population-Based Pilot.

Advancements in therapies for Duchenne muscular dystrophy (DMD) have made diagnosis within the newborn period a high priority. We undertook a consortia approach to advance DMD newborn screening in the United States. This manuscript describes the formation of the Duchenne Newborn Screening Consortium, the development of the pilot protocols, data collection tools including parent surveys, and findings from the first year of a two-year pilot. The DMD pilot design is population-based recruitment of infants born in New York State. Data tools were developed to document the analytical and clinical validity of DMD NBS, capture parental attitudes, and collect longitudinal health information for diagnosed newborns. Data visualizations were updated monthly to inform the consortium on enrollment. After 12 months, 15,754 newborns were screened for DMD by the New York State Newborn Screening (NYS NBS) Program. One hundred and forty screened infants had borderline screening results, and sixteen infants were referred for molecular testing. Three male infants were diagnosed with dystrophinopathy. Data from the first year of a two-year NBS pilot for DMD demonstrate the feasibility of NBS for DMD. The consortia approach was found to be a useful model, and the Newborn Screening Translational Research Network's data tools played a key role in describing the NBS pilot findings and engaging stakeholders.

Nontargeted Analysis of Face Masks: Comparison of Manual Curation to Automated GCxGC Processing Tools.

Masks constructed of a variety of materials are in widespread use due to the COVID-19 pandemic, and people are exposed to chemicals inherent in the masks through inhalation. This work aims to survey commonly available mask materials to provide an overview of potential exposure. A total of 19 mask materials were analyzed using a nontargeted analysis two-dimensional gas chromatography (GCxGC)-mass spectrometric (MS) workflow. Traditionally, there has been a lack of GCxGC-MS automated high-throughput screening methods, resulting in trade-offs with throughput and thoroughness. This work addresses the gap by introducing new machine learning software tools for high-throughput screening (Floodlight) and subsequent pattern analysis (Searchlight). A recursive workflow for chemical prioritization suitable for both manual curation and machine learning is introduced as a means of controlling the level of effort and equalizing sample loading while retaining key chemical signatures. Manual curation and machine learning were comparable with the mask materials clustering into three groups. The majority of the chemical signatures could be characterized by chemical class in seven categories: organophosphorus, long chain amides, polyethylene terephthalate oligomers, n-alkanes, olefins, branched alkanes and long-chain organic acids, alcohols, and aldehydes. The olefin, branched alkane, and organophosphorus components were primary contributors to clustering, with the other chemical classes having a significant degree of heterogeneity within the three clusters. Machine learning provided a means of rapidly extracting the key signatures of interest in agreement with the more traditional time-consuming and tedious manual curation process. Some identified signatures associated with plastics and flame retardants are potential toxins, warranting future study to understand the mask exposure route and potential health effects.

The Human Phenotype Ontology in 2021.

The Human Phenotype Ontology (HPO, https://hpo.jax.org) was launched in 2008 to provide a comprehensive logical standard to describe and computationally analyze phenotypic abnormalities found in human disease. The HPO is now a worldwide standard for phenotype exchange. The HPO has grown steadily since its inception due to considerable contributions from clinical experts and researchers from a diverse range of disciplines. Here, we present recent major extensions of the HPO for neurology, nephrology, immunology, pulmonology, newborn screening, and other areas. For example, the seizure subontology now reflects the International League Against Epilepsy (ILAE) guidelines and these enhancements have already shown clinical validity. We present new efforts to harmonize computational definitions of phenotypic abnormalities across the HPO and multiple phenotype ontologies used for animal models of disease. These efforts will benefit software such as Exomiser by improving the accuracy and scope of cross-species phenotype matching. The computational modeling strategy used by the HPO to define disease entities and phenotypic features and distinguish between them is explained in detail.We also report on recent efforts to translate the HPO into indigenous languages. Finally, we summarize recent advances in the use of HPO in electronic health record systems.